Not FDA approved and sold as a research chemical. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Adipotide

Not FDA approved

Vascular-targeting peptidomimetic

Also known as: FTPP, prohibitin-targeting peptide, HKPao, orb1981129, DA-74204, T76315

Evidence score

21/ 100

Thin evidence

Very thin human evidence

Regulatory standing. Sold as a research chemical, not approved
Animal / preclinical only. Evidence is largely animal or in-vitro
No registered human trials. Nothing registered on ClinicalTrials.gov
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Adipotide, also called FTPP or prohibitin-targeting peptide, is an experimental synthetic peptide designed to bind prohibitin on blood vessels that supply white fat tissue. It links this targeting sequence to a pro-apoptotic sequence, with the aim of triggering cell death in those vessels and so reducing fat tissue.

What the evidence shows

Automatic summaryAnimal / preclinical

Evidence comes mainly from animal studies, including rodents and obese monkeys, where weight loss was reported alongside signs of kidney toxicity. There are no registered human trials in the provided data, so its effects and safety in people are not established.

Key facts

Molecular formula

C111H206N36O28S2

Molecular weight

2557.2 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

0registered studies

Nonemost advanced phase

0completed (sample)

0recruiting (sample)

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

3papers referencing Adipotide

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.

Sci Transl Med2011

A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication.

J Control Release2013

Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys".

Sci Transl Med2012

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.